Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > ORGANIZATION
ORGANIZATION
- Yokokura Wins 4th Term to Lead Japan Medical Association
June 25, 2018
- Expand Exemption Criteria in New Off-Patent Price Cut Rule: Japan Pharma Lobby
June 19, 2018
- Japan Pharma Group Calls for Careful Approach on PMP Deduction for Comparator Drugs
June 19, 2018
- Don’t Make Coverage Decision on CEA, Tweak Prices with Limited Scope: FPMAJ
June 18, 2018
- Scrap Unfair Company Criteria for Price Maintenance Premium: Japan Trade Group
June 18, 2018
- FPMAJ Welcomes Chuikyo’s Openness to Views of Experts on CEA: Drug Pricing Committee Chair
June 18, 2018
- Atsushi Kamide of Astellas Elected as New Chairman of FPMAJ’s Drug Pricing Committee
June 18, 2018
- Hiroki Nakatani Named as New Board Chair for GHIT Fund
June 8, 2018
- JPMA Proposes Creation of Disease Registry to Employ Medical Data
June 5, 2018
- New JPMA Chief Calls for Scrapping PMP Company Criteria
June 1, 2018
- Sawai President Elected New Generic Industry Chief
May 30, 2018
- Drug Damage Watchdog Submits Opinion to Health Ministry, Opposing Current Conditional Early Approval System
May 30, 2018
- Big Data Analysis Finds Low Generic Drug Use Rate among Healthcare Professionals: Kyokai Kenpo
May 28, 2018
- Daiichi Sankyo CEO Nakayama Appointed as New President of JPMA
May 25, 2018
- Isao Teshirogi Elected New FPMAJ Chairman
May 25, 2018
- PhRMA Vision Report Stresses Innovation as Investment for Healthier Lifespans
May 17, 2018
- Over 80% Concerned about Restrictions on Access to Prescription Drugs: PhRMA Survey
May 15, 2018
- Drug Damage Watchdog Calls for 3rd Party Long-Term Investigation for HPV
May 2, 2018
- PhRMA/EFPIA Deeply Concerned about MOF Pitch on Stringent CEA Application
April 26, 2018
- PhRMA/EFPIA Say Humira, Jevtana, Xarelto Lost Eligibility under New PMP, Innovation Not Appropriately Defined
April 26, 2018
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…